Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sinovac 23-valent PPV in population aged 2 years and older
NCT05477693Phase 4Completed
- Sponsor
- Sinovac Biotech Ltd.
- Start
- Oct 2022
- Primary completion
- Apr 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of Sinovac 23-valent pneumococcal polysaccharide vaccine in pneumococcal infection, sponsored by Sinovac Biotech Ltd.. Started Oct 2022; status: completed.
02
Drugs
Sinovac 23-valent pneumococcal polysaccharide vaccine
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT05477693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05477693.